Study of the Safety and Immunogenicity of an Adenovirus-based Tuberculosis Vaccine
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00800670 |
Recruitment Status :
Terminated
(Study was terminated after the low dose cohort had been enrolled)
First Posted : December 2, 2008
Last Update Posted : September 8, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Tuberculosis | Biological: Ad5Ag85A | Phase 1 |
As the global tuberculosis (TB) epidemic continues, the incidence of latent and active TB is expected to rise. HIV-infected persons are especially susceptible to TB. An improved TB vaccine over the present BCG vaccine is needed.
The general objectives of our TB vaccine research program are to develop a safe and effective vaccine for persons who at increased risk of contracting TB or reactivating latent tuberculosis and develop a safe booster vaccine for persons who have been previously vaccinated with BCG.
This is an open-labeled phase 1 single institution trial investigating a recombinant genetic TB vaccine AdAg85A given by intramuscular injection in healthy subjects with or without a history of BCG vaccination. Ad5Ag85A is a recombinant replication-deficient adenoviral vector expressing an M. tuberculosis immunogenic antigen Ag85A. We have shown that it is safe, immunogenic and associated with enhanced protection against challenge with virulent M Tb in murine, bovine and guinea pig models. Clinical grade AdAg85A has been manufactured by the Robert E Fitzhenry Vector Laboratory, Centre for Gene Therapeutics, McMaster University, Hamilton, Ontario, Canada.
The effect of pre-existing adenovirus antibodies on the safety and immunogenicity of the recombinant AdTB vaccine will be evaluated and the results of the PPD skin test following vaccination evaluated in a subset of subjects with a history of a negative PPD skin test.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 24 participants |
Allocation: | Non-Randomized |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Prevention |
Official Title: | Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of an Adenovirus-based Tuberculosis Vaccine |
Study Start Date : | June 2009 |
Actual Primary Completion Date : | December 2012 |
Actual Study Completion Date : | July 2013 |

Arm | Intervention/treatment |
---|---|
Experimental: Lower dose
Lower dose of Ad5Ag85A: 10^8pfu
|
Biological: Ad5Ag85A
Single intra-muscular administration of 10^8 pfu of recombinant-deficient human adenoviral TB vaccine (Ad5Ag85A) |
Experimental: Higher dose
Higher dose of vaccine Ad5Ag85A: 10^9pfu
|
Biological: Ad5Ag85A
Single intra-muscular administration of 10^9 recombinant-deficient human adenoviral TB vaccine (Ad5Ag85A) |
- Local and systemic signs and symptoms and laboratory toxicity [ Time Frame: 24 weeks ]
- Immunogenicity will be compared among the groups by determining the level and quantity of antigen-specific T cells by human interferon ELISA and Elispot assay [ Time Frame: 24 weeks ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 55 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Healthy human subjects who are between 18 and 55 years of age with or without a history of BCG vaccination.
- HIV antibody negative
- For women, negative pregnancy test and practising two acceptable forms of contraception for the duration of the study (barrier contraceptive, birth control pill, surgically sterile, post-menopausal 2yrs, abstinence)
- For men, using barrier contraception for the duration of the study
Exclusion Criteria:
- Pregnant or lactating women
- Subjects who have any acute or chronic illnesses including active tuberculosis or receiving any drug treatment in the opinion of the investigator likely to affect the immune system.
- Subjects with symptoms suggestive of an upper respiratory tract infection (including cough, runny nose, or sore throat)
- Subjects who have a history of active or latent TB infection or whose PBMCs are strongly responsive to ESAT6/CFP10 stimulation using a commercial interferon gamma release assay for TB [consistent with latent TB infection].
- Subjects who have laboratory values outside the normal range.
- Not available for scheduled follow-up visits. Subjects enrolled in the trial must be followed at 7 days, and then at 2, 4, 8, 16 and 24 weeks post-vaccination.
- Failure to provide written consent.
- Known allergy to vaccine components
- Known exposure to active TB within past 6 months or subjects whose occupation puts them at increased risk of TB exposure (based on Hamilton Health Science/St Joseph Healthcare list of high risk personnel)
- Any abnormality on chest x-ray suggestive of active or remote tuberculosis infection.
- PPD skin test within last 12 months
- BCG status unknown

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00800670
Canada, Ontario | |
McMaster University Medical Centre | |
Hamilton, Ontario, Canada, L8N 3Z5 |
Principal Investigator: | Zhou Xing, PhD | McMaster University | |
Principal Investigator: | Fiona M Smaill, MD | McMaster University |
Responsible Party: | Fiona Smaill, Professor and Chair, McMaster University |
ClinicalTrials.gov Identifier: | NCT00800670 |
Other Study ID Numbers: |
REB 09-001 |
First Posted: | December 2, 2008 Key Record Dates |
Last Update Posted: | September 8, 2017 |
Last Verified: | September 2017 |
tuberculosis vaccine adenovirus |
Tuberculosis Adenoviridae Infections Mycobacterium Infections Actinomycetales Infections Gram-Positive Bacterial Infections |
Bacterial Infections Bacterial Infections and Mycoses Infections DNA Virus Infections Virus Diseases |